T. Rowe Price Associates
BCAX

T. Rowe Price Associates’s Bicara Therapeutics BCAX Stock Holding History

T. Rowe Price Associates’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.5M Buy
1,904,248
+528,050
+38% +$11.8M 0.01% 858
2026
Q1 		$27.4M Sell
1,376,198
-183,337
-12% -$3.16M ﹤0.01% 956
2025
Q4 		$26.2M Sell
1,559,535
-195,876
-11% -$3.35M ﹤0.01% 999
2025
Q3 		$27.7M Sell
1,755,411
-394,899
-18% -$4.42M ﹤0.01% 975
2025
Q2 		$20M Buy
2,150,310
+352,289
+20% +$4.2M ﹤0.01% 958
2025
Q1 		$23.4M Buy
1,798,021
+250,841
+16% +$3.33M ﹤0.01% 917
2024
Q4 		$27M Buy
1,547,180
+8,246
+0.5% +$172K ﹤0.01% 923
2024
Q3 		$39.2M Buy
+1,538,934
New +$39.2M ﹤0.01% 817

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates's BCAX Position: Q2 2026 in Review

T. Rowe Price Associates increased its Bicara Therapeutics (BCAX) stake by 38% in Q2 2026, buying an estimated $11.8M and bringing the position to 1,904,248 shares worth $56.5M. The position accounts for 0.01% of the portfolio, ranked #858.

T. Rowe Price Associates first reported a position in BCAX in Q3 2024 and has held it in 8 quarters since. 171 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • T. Rowe Price Associates held 1,904,248 shares of Bicara Therapeutics worth $56.5M as of Q2 2026.
  • T. Rowe Price Associates bought 528,050 Bicara Therapeutics shares in Q2 2026, an estimated $11.8M.
  • Bicara Therapeutics made up 0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #858 holding.
  • T. Rowe Price Associates first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 171 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.